As of 1 February 2021, a couple of updates have come into effect which may be of interest to, or impact those living with arthritis.
As of 1 February, all prescriptions in Australia must now include the medication's active ingredient, rather than the brand name. This is called active ingredient prescribing.
This change is part of an Australian Government initiative and means the way medicine information looks on your prescriptions is changing.
We've gathered the below helpful links to help you learn more about this change, and what this means for you:
Active
ingredient prescribing: all you need to know
Consumer resource by NPS Medicinewise, published 9 September 2020
Doctors
must now prescribe drugs using their chemical name, not brand name. That's good news for patients
Article by The Conversation, published 1 February 2021
In December 2020, the Therapeutic Goods Administration (TGA) announced that low-dose cannabidiol (CBD) containing products, up to a maximum of 150 mg/day, for use in adults, can be supplied over-the-counter by a pharmacist, without a prescription. This came into affect on 1 February 2021.
This decision limits over-the-counter supply to only those products that are approved by the TGA and included on the Australian Register of
Therapeutic Goods (ARTG). Currently, there are no TGA approved products on the ARTG. More information:
Over-the-counter access to
low dose cannabidiol
Media release from the TGA, published 15 December 2020
Medicinal cannabis: Information for consumers
Therapeutic Goods Administration
Medicinal cannabis explained
Consumer resource, NPS Medicinewise
You can make a difference by supporting the work of Arthritis Queensland. Arthritis Queensland is 95% community funded. We rely on our generous donors and volunteers to ensure that we can continue to provide solutions and support to adults and children living with the pain of arthritis.